Intervention

Aumolertinib

ClinicalTrials.gov intervention label

Clinical trials8
Recruiting2
Common conditions4
Lead sponsors shown7

Clinical trials

8 shown
A Study of Aumolertinib in European Participants With Non-Small Cell Lung CancerNCT07130916 · 2024-12-05
RECRUITING
A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerNCT06417008 · 2024-05-28
RECRUITING
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCNCT07183189 · 2025-10-30
ACTIVE_NOT_RECRUITING
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung CancerNCT06752408 · 2024-12-17
NOT_YET_RECRUITING
Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).NCT06227897 · 2024-06-01
WITHDRAWN
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.NCT05946460 · 2023-08-15
UNKNOWN
Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade PatternsNCT04922138 · 2022-01-14
UNKNOWN
Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR MutationsNCT04923906 · 2021-08-11
ACTIVE_NOT_RECRUITING

Trial status mix

ACTIVE_NOT_RECRUITING2
RECRUITING2
UNKNOWN2
NOT_YET_RECRUITING1
WITHDRAWN1

Phase mix

PHASE25
PHASE33
PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.